Benjamin P. Geisler
@ben-geisler.com
Stipendiat in Oslo, 🇳🇴 | prior hospitalist | Stuck between 3 continents/still fresh off the boat | RT≠opinion≠others'
Economics
45%
Medicine
32%
This book was started by the wonderful Hugo Torres and Priyank Jain and the series by Michael Hochman.
Great post in Bob Wachter's new substack:
Will A.I. kill health care jobs, too (and not just coders', Uber drivers', or those in admin, manufacturing, retail ...)?
Bob's conclusion: yes, but it may not be the clinical jobs!
CDI? Compliance? More so!
substack.com/inbox/p...
Will A.I. kill health care jobs, too (and not just coders', Uber drivers', or those in admin, manufacturing, retail ...)?
Bob's conclusion: yes, but it may not be the clinical jobs!
CDI? Compliance? More so!
substack.com/inbox/p...
New in Lancet Oncol: Which occupations have the highest cancer deaths?
For ♂s it was the rather broad construction/extraction category, for ♀s the transportation one.
Statisticians, chiropractors, & funeral directors had the highest breast cancer risk
http://bit.ly/4aZLP9c
For ♂s it was the rather broad construction/extraction category, for ♀s the transportation one.
Statisticians, chiropractors, & funeral directors had the highest breast cancer risk
http://bit.ly/4aZLP9c
Hospital medicine is evolving fast!
50 Studies Every Hospitalist Should Know (OUP), co-edited w/ Jeff & Kathy, distills landmark trials for everyday inpatient decisions -- who was studied, effect sizes, and key limits beyond guidelines.
Pre-order paperback (ebook coming): www.amazon.com/Studi...
50 Studies Every Hospitalist Should Know (OUP), co-edited w/ Jeff & Kathy, distills landmark trials for everyday inpatient decisions -- who was studied, effect sizes, and key limits beyond guidelines.
Pre-order paperback (ebook coming): www.amazon.com/Studi...
Landmark UK-US pharmaceuticals deal to safeguard medicines access and drive vital investment for UK patients and businesses
Milestone deal secures UK’s medicines access for patients, with a wide range of groundbreaking new treatments to reach NHS front-line quicker.
www.gov.uk
🇬🇧🇺🇸 NICE raising cost-effectiveness threshold 25% (£20-30k→£25-35k/QALY) as part of UK-US pharma deal with 0% tariffs.
Concern: Will funding for new drugs displace mental health services in fixed NHS budgets?
Concern: Will funding for new drugs displace mental health services in fixed NHS budgets?
🔥 Don't miss THE debate of #SMDM2026 in Oslo: Tomas Philipson vs. Karl Claxton debate drug pricing & value of innovation. Two heavyweights with ?opposing views. Moderated by Mark Sculpher. Hoping for fireworks and that this is going to be epic.
smdm.org/meeting/48t...
smdm.org/meeting/48t...
"'It's going much too fast': the inside story of the race to create the ultimate AI
In Silicon Valley, rival companies are spending trillions of dollars to reach a goal that could change humanity – or potentially destroy it"
Guardian Interactive story:
www.theguardian.com/...
In Silicon Valley, rival companies are spending trillions of dollars to reach a goal that could change humanity – or potentially destroy it"
Guardian Interactive story:
www.theguardian.com/...
Keynote
smdm.org
Exciting news! Prof. Sander van der Linden - leading expert on misinformation & decision-making - announced as keynote for @smdm.bsky.social 2026 in Oslo! June 28-July 1. Save the date! 🎉🇳🇴
smdm.org/meeting/page...
smdm.org/meeting/page...
Benjamin P. Geisler
@ben-geisler.com
· Nov 25
I was an immigrant physician (even though I did not have an H-1B visa).
The threat that the H-1B visa fees pose to U.S. health care is real. It will first hit rural teaching hospitals. They will have to decrease available beds/appointment slots.
www.npr.org/sections...
The threat that the H-1B visa fees pose to U.S. health care is real. It will first hit rural teaching hospitals. They will have to decrease available beds/appointment slots.
www.npr.org/sections...
Benjamin P. Geisler
@ben-geisler.com
· Oct 30
EVERDAC is hot off press @esicm.bsky.social #Lives2025 in @nejm.org open access currently:
www.nejm.org/doi/full/10....
Reports that in (non-blinded trial) patients with shock, management *without* early a-line insertion was noninferior to early catheter insertion…. #Lives2025 #criticalcare
www.nejm.org/doi/full/10....
Reports that in (non-blinded trial) patients with shock, management *without* early a-line insertion was noninferior to early catheter insertion…. #Lives2025 #criticalcare
Deferring Arterial Catheterization in Critically Ill Patients with Shock | NEJM
In patients with shock, whether noninvasive blood-pressure monitoring is an effective
alternative to the recommended use of an arterial catheter is uncertain. In this multicenter,
open-label, nonin...
www.nejm.org
.. and a non-inferiority trial in shock all-comers (although this has already crept into practice -though that's dependent on center and attending- so this trial is prolly less of a surprise)
Benjamin P. Geisler
@ben-geisler.com
· Oct 30
ANDROMEDA-SHOCK-2 is up next…. this looks at personalised phenotype-based, capillary refill time (CRT) targeted resuscitation in early septic shock, comparing to standard resuscitation. It is large (86 centres, 19 countries).
Read it free from JAMA: tinyurl.com/mjcj8s5w
#Lives2025 #criticalcare
Read it free from JAMA: tinyurl.com/mjcj8s5w
#Lives2025 #criticalcare
Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock
This randomized clinical trial examines whether a personalized hemodynamic resuscitation protocol targeting capillary refill time was more effective than usual care in patients with early septic shock...
tinyurl.com
Whoa: two potentially paradigm-shifting new shock trials - one in early septic shock..
Reposted by Benjamin P. Geisler
Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock
This randomized clinical trial examines whether a personalized hemodynamic resuscitation protocol targeting capillary refill time was more effective than usual care in patients with early septic shock...
tinyurl.com
ANDROMEDA-SHOCK-2 is up next…. this looks at personalised phenotype-based, capillary refill time (CRT) targeted resuscitation in early septic shock, comparing to standard resuscitation. It is large (86 centres, 19 countries).
Read it free from JAMA: tinyurl.com/mjcj8s5w
#Lives2025 #criticalcare
Read it free from JAMA: tinyurl.com/mjcj8s5w
#Lives2025 #criticalcare
Reposted by Benjamin P. Geisler
Deferring Arterial Catheterization in Critically Ill Patients with Shock | NEJM
In patients with shock, whether noninvasive blood-pressure monitoring is an effective
alternative to the recommended use of an arterial catheter is uncertain. In this multicenter,
open-label, nonin...
www.nejm.org
EVERDAC is hot off press @esicm.bsky.social #Lives2025 in @nejm.org open access currently:
www.nejm.org/doi/full/10....
Reports that in (non-blinded trial) patients with shock, management *without* early a-line insertion was noninferior to early catheter insertion…. #Lives2025 #criticalcare
www.nejm.org/doi/full/10....
Reports that in (non-blinded trial) patients with shock, management *without* early a-line insertion was noninferior to early catheter insertion…. #Lives2025 #criticalcare
Benjamin P. Geisler
@ben-geisler.com
· Oct 24
Teaching machines to doubt
Nature Medicine - We must build safeguards against AI’s most dangerous feature: its ability to stop us thinking critically.
www.nature.com
Leo Celi's latest in Nature Medicine: "Teaching machines to doubt."
As we rush to deploy A.I. in healthcare, teaching algorithms to recognize their own limitations isn't just good science, it's a patient safety thing.
Worth your time.
As we rush to deploy A.I. in healthcare, teaching algorithms to recognize their own limitations isn't just good science, it's a patient safety thing.
Worth your time.
Benjamin P. Geisler
@ben-geisler.com
· Oct 17
Today I learned that AOL still has an email service (from the John Bolton indictment)
Benjamin P. Geisler
@ben-geisler.com
· Oct 15
Sue Goldie Has Parkinson’s Disease
An acclaimed researcher is an expert at explaining complicated problems. Now she has to confront the most vexing question: What is happening to her?
www.nytimes.com
Professor Sue Goldie is a masterful educator and storyteller.
She decided to share her diagnosis on her own terms and brings up things here about Parkinson's (and about triathlons as a PD treatment) that no one ever does
www.nytimes.com/interactive/...
She decided to share her diagnosis on her own terms and brings up things here about Parkinson's (and about triathlons as a PD treatment) that no one ever does
www.nytimes.com/interactive/...
Benjamin P. Geisler
@ben-geisler.com
· Oct 3
“Very rarely a chance of heart attack or death” – Wait, what?
Hospitalists frequently discuss the risks associated with tests, treatments, and/or surgical procedures with their patients. But is everyone in the clear on what a “slight risk of complications” actually means? A session on the meaning of risk to patients and how to effectively communicate risk was discussed at SHM Converge 2025, the annual meeting of the Society of Hospitalist Medicine held in Las Vegas in April.
healthcare-in-europe.com
A stress test with a slight chance of MI or death... 😕
Do patients truly understand the risks we communicate?
European Hospital features discussion on medical risk communication across different cultures & systems.
Do patients truly understand the risks we communicate?
European Hospital features discussion on medical risk communication across different cultures & systems.
Benjamin P. Geisler
@ben-geisler.com
· Sep 29
Pure gold from Adam Rodman on overconfidence of reasoning models. Does this mirror incompetent + overconfident residents?
x.com/AdamRodmanMD/s... (yes, X, but worth your while)
x.com/AdamRodmanMD/s... (yes, X, but worth your while)
Benjamin P. Geisler
@ben-geisler.com
· Sep 22
Jimmy Kimmel Reveals Details of His Son’s Birth & Heart Disease
Jimmy and his wife Molly welcomed their second child together, William “Billy” Kimmel. At three days old, Billy had successful open heart surgery at Children’s Hospital Los Angeles and is now home with his family. Jimmy opens up about his son’s birth and health complications and encourages donations
www.youtube.com
Jimmy Kimmel on pre-existing conditions
Benjamin P. Geisler
@ben-geisler.com
· Sep 22
Jimmy Kimmel on Elementary School Shooting in Uvalde, Texas
Jimmy responds to the tragic school shooting at Robb Elementary School in Uvalde, Texas, and talks about 89% of Americans wanting background checks, our cowardly leaders listening to the NRA instead of the people they actually represent, firearms becoming the #1 leading cause of death for American c
youtu.be
Jimmy Kimmel on school shootings:
Benjamin P. Geisler
@ben-geisler.com
· Sep 19
Associate professor (UHD) in Health Economics and Modelling (Fulltime/permanent)
We are seeking an experienced health economist with proven modelling and analytics skills to join our HTA department. The successful candidate will lead and collaborate on high-impact research projects, develop grant applications, supervise PhD and …
www.academictransfer.com
🌟 Amazing opportunity! 🌟
Our EU project partner @erasmusuni seeks Associate Prof in Health Economics & Modelling! 📈🏥 Join 100+ health economists in Rotterdam 🇳🇱
Check it out here and apply today:
www.academictransfer...
#HealthEconomics #HEOR #AcademicJobs
Our EU project partner @erasmusuni seeks Associate Prof in Health Economics & Modelling! 📈🏥 Join 100+ health economists in Rotterdam 🇳🇱
Check it out here and apply today:
www.academictransfer...
#HealthEconomics #HEOR #AcademicJobs
Benjamin P. Geisler
@ben-geisler.com
· Sep 9
Apixaban for Extended Treatment of Provoked Venous Thromboembolism | NEJM
The appropriate duration of anticoagulation for venous thromboembolism (VTE) in patients
who have a transient provoking factor (e.g., surgery, trauma, or immobility) and concomitant
enduring risk f...
www.nejm.org
Bottom Line: Extended low-dose apixaban significantly reduces recurrent VTE in patients with provoked VTE + enduring risk factors, with low major bleeding risk. This will likely change practice and guidelines.
www.nejm.org/doi/ful...
8/8
www.nejm.org/doi/ful...
8/8
Benjamin P. Geisler
@ben-geisler.com
· Sep 9
Clinical Implications: The 10% recurrence rate in placebo group suggests "provoked" VTE with enduring risk factors may have similar recurrence risk to "unprovoked" VTE. Simple provoked vs unprovoked categorization may be insufficient for treatment decisions.
7/8
7/8
Benjamin P. Geisler
@ben-geisler.com
· Sep 9
Study Population: Mean age 59.5 years, 57% female. Most common provoking factors: surgery (33.5%), immobility (31.3%), trauma (19.2%). Most common enduring risk factors: chronic inflammatory disease (52.2%), obesity BMI≥30 (48.2%), atherosclerotic CVD (29.3%).
6/8
6/8
Benjamin P. Geisler
@ben-geisler.com
· Sep 9
Safety Events: Major bleeding: 0.3% (apixaban) vs 0% (placebo). Clinically relevant non-major bleeding: 4.8% vs 1.7% (HR 2.68, P=0.06). One major bleed was a 3mm subdural hematoma after horse fall - no hospitalization required.
5/8
5/8
Benjamin P. Geisler
@ben-geisler.com
· Sep 9
Primary Results: Symptomatic recurrent VTE occurred in 1.3% (apixaban) vs 10.0% (placebo)
- an 87% relative risk reduction (HR 0.13, 95% CI 0.04-0.36, p<0.001)
Number needed to treat = 12
4/8
- an 87% relative risk reduction (HR 0.13, 95% CI 0.04-0.36, p<0.001)
Number needed to treat = 12
4/8
Benjamin P. Geisler
@ben-geisler.com
· Sep 9
Study Design: HI-PRO was a randomized, double-blind, placebo-controlled trial.
600 patients with provoked VTE + ≥1 enduring risk factor received apixaban 2.5mg BID vs. placebo for 12 months after completing ≥3 months of initial anticoagulation.
3/8
600 patients with provoked VTE + ≥1 enduring risk factor received apixaban 2.5mg BID vs. placebo for 12 months after completing ≥3 months of initial anticoagulation.
3/8
Benjamin P. Geisler
@ben-geisler.com
· Sep 9
Background: Current guidelines recommend 3-6 months of anticoagulation for provoked VTE (surgery, trauma, immobility).
What about patients with enduring risk factors like obesity, chronic lung disease, or autoimmune disorders?
2/8
What about patients with enduring risk factors like obesity, chronic lung disease, or autoimmune disorders?
2/8
Benjamin P. Geisler
@ben-geisler.com
· Sep 9
🧵 HI-PRO trial from @escardio: low-dose apixaban _long-term_ for "provoked" VTE
This will likely be practice-changing: HI-PRO challenges the current practice re: anticoagulation duration for "provoked" VTE
1/8 📊
This will likely be practice-changing: HI-PRO challenges the current practice re: anticoagulation duration for "provoked" VTE
1/8 📊